Johnson & Johnson

JNJ ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2019 FY2018 FY2017
Operating Activities
Net Income $26.80B $14.07B $35.15B $20.88B $14.71B $15.12B $15.30B $1.30B
Depreciation & Amortization $7.50B $7.34B $7.49B $7.39B $7.23B $7.01B $6.93B $5.64B
Depreciation — — — — — — — —
Amortization $4.60B $4.50B $4.50B $4.20B $4.70B $4.50B $4.40B $3.00B
Stock-Based Compensation $1.35B $1.18B $1.16B $1.14B $1.01B $977.0M $978.0M $962.0M
Net Cash from Operating Activities $24.53B $24.27B $22.79B $23.41B $23.54B $23.42B $22.20B $21.06B
Investing Activities
Capital Expenditures $4.83B $4.42B $4.54B $3.65B $3.35B $3.50B $3.67B $3.28B
Business Acquisitions $17.54B $15.15B $0 $60.0M $7.32B $5.81B $899.0M $35.15B
Net Cash from Investing Activities $-23.59B $-18.60B $878.0M $-8.68B $-20.83B $-6.19B $-3.17B $-14.87B
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases $5.95B $2.43B $5.05B $3.46B $3.22B $6.75B $5.87B $6.36B
Net Cash from Financing Activities $-5.54B $-3.13B $-15.83B $-14.05B $-6.12B $-18.02B $-18.51B $-7.67B
Net Change in Cash $-4.40B $2.25B $7.73B $502.0M $-3.32B $-802.0M $283.0M $-1.15B
Free Cash Flow $19.70B $19.84B $18.25B $19.76B $20.19B $19.92B $18.53B $17.78B
← Newer Page 1 of 2 Older →